RUNX2 and neoplasm: A recent comprehensive bioinformatics study tested 14 tumour-suppressor and 3194 druggable genes (including RUNX1, RUNX2, and RUNX3) using functional similarity and differential gene expression analysis for SL interaction identification in HCC, and a total of 272 potential SL pairs were revealed, whilst RUNX genes did not pass initial screening tests [165].